TuHURA Biosciences, Inc./NV 8-K/A

What Happened TuHURA Biosciences (HURA) filed an amendment on April 30, 2026 to its April 8, 2026 Form 8‑K solely to correct errors in the previously provided unaudited pro forma condensed combined statement of operations for the year ended December 31, 2025. The pro formas reflect the company’s acquisition of Kineta, Inc., which closed on June 30, 2025 under the Merger Agreement dated December 11, 2024 (as amended May 5, 2025). The corrected pro forma statements replace Exhibit 99.1 from the prior report; no other updates or changes were made to the earlier filing.

Key Details

• Acquisition closed: June 30, 2025 (transaction implemented via a two-step merger with Merger Sub I and Merger Sub II).
• Merger Agreement: dated December 11, 2024; amended May 5, 2025.
• Prior report filed: Current Report on Form 8‑K on April 8, 2026; amended 8‑K filed April 30, 2026 to correct pro formas.
• Filing replaces Exhibit 99.1 with the corrected unaudited Pro Forma Condensed Combined Statement of Operations for the year ended December 31, 2025 and accompanying notes.

Why It Matters Pro forma financial statements are used by investors to evaluate how an acquisition would have affected historical results; correcting errors in those statements can change analysis of the combined company's 2025 operating picture. Because this amendment only replaces the prior pro formas and does not change other disclosures, investors should review the revised Exhibit 99.1 and its notes to see if the corrections affect their valuation or comparability assumptions. The amended filing also reiterates the company’s forward‑looking statement caution and points investors to the company’s SEC filings for more information.